Synthetic peptide amides and dimers thereof
The invention relates to synthetic peptide amide ligands of the kappa opioid receptor and particularly to agonists of the kappa opioid receptor that exhibit low P 450 CYP inhibition and low penetration into the brain. The synthetic peptide amides of the invention conform to the structure: The compounds are useful in the prophylaxis and treatment of pain and inflammation associated with a variety of diseases and conditions.
1. A method of treating, inhibiting or preventing a kappa opioid receptor-associated disease or condition in a human patient or a mammal, wherein the kappa opioid receptor-associated disease or condition is pruritis (also known as pruritus), the method comprising:
administering to the human patient or the mammal a composition comprising an effective amount of a synthetic peptide amide having the formula:
or a stereoisomer, mixture of stereoisomers, pharmaceutically acceptable salt, hydrate, acid salt hydrate, or N-oxide thereof,
wherein
Xaa 1 is independently selected from the group consisting of (A)(A′)D-Phe, (A)(A′)(a-Me)D-Phe, D-Tyr, D-Tic, D-tert-leucine, D-neopentylglycine, D-phenylglycine, D-homophenylalanine, and β-(E)D-Ala, wherein each (A) and each (A′) are phenyl ring substituents independently selected from the group consisting of —H, —F, —Cl, —NO 2 , —CH 3 , —CF 3 , —CN, —CONH 2 , and wherein each (E) is independently selected from the group consisting of cyclobutyl, cyclopentyl, cyclohexyl, pyridyl, thienyl and thiazolyl;
Xaa 2 is independently selected from the group consisting of (A)(A′)D-Phe, (A)(A′)(a-Me)D-Phe, D-1Nal, D-2Nal, D-Tyr, (E)D-Ala, and D-Trp;
wherein p is 1;
Xaa 3 -Xaa 4 - is selected from the group consisting of D-Nle-(B) 2 D-Arg-, D-Leu-δ-(B) 2 α-(B′)D-Orn-, and (α-Me)D-Leu-δ(B) 2 -α(B′)D-Orn-;
wherein G is
and the moiety
is an optionally substituted 4 to 8-membered heterocyclic ring moiety wherein all ring heteroatoms in said ring moiety are N; wherein Y and Z are each independently C or N; provided that when such ring moiety is a six, seven or eight-membered ring, Y and Z are separated by at least two ring atoms; and provided that when such ring moiety has a single heteroatom which is N, then such ring moiety is non-aromatic;
wherein W is selected from the group consisting of:
null, provided that when W is null, Y is N;
NH—(CH 2 ) b — with b equal to zero, 1, 2, 3, 4, 5, or 6; and
NH—(CH 2 ) c —O— with c equal to 2, or 3;
wherein V is C 1 -C 6 alkyl, and e is zero or 1, wherein when e is zero, then V is null and, R 1 and R 2 are directly bonded to the same or different ring atoms;
wherein (a) R 1 is —H, —OH, halo, CF 3 , —NH 2 , —COOH, C 1 -C 6 alkyl, amidino, C 1 -C 6 alkyl-substituted amidino, aryl, optionally substituted heterocyclyl, Pro-amide, Pro, Gly, Ala, Val, Leu, Ile, Lys, Arg, Orn, Ser, Thr, CN, CONH 2 , COR′, SO 2 R′, CONR′R″, NHCOR′, OR′, or SO 2 NR′R″; wherein said optionally substituted heterocyclyl is optionally singly or doubly substituted with substituents independently selected from the group consisting of C 1 -C 6 alkyl, —C 1 -C 6 alkoxy, oxo, —OH, —Cl, —F, —NH 2 , —NO 2 , —CN, —COOH, and amidino; wherein R′ and R″ are each independently —H, C 1 -C 8 alkyl, aryl, heterocyclyl or R′ and R″ are combined to form a 4- to 8-membered ring, which ring is optionally substituted singly or doubly with substituents independently selected from the group consisting of C 1 -C 6 alkyl, —C 1 -C 6 alkoxy, —OH, —Cl, —F, —NH 2 , —NO 2 , —CN, —COOH and amidino; and R 2 is H, amidino, singly or doubly C 1 -C 6 alkyl-substituted amidino, —CN, —CONH 2 , —CONR′R″, —NHCOR′, —SO 2 NR′R″, or —COOH; or
(b) R 1 and R 2 taken together can form an optionally substituted 4- to 9-membered heterocyclic monocyclic or bicyclic ring moiety which is bonded to a single ring atom of the Y and Z-containing ring moiety; or
(c) R 1 and R 2 taken together with a single ring atom of the Y and Z-containing ring moiety can form an optionally substituted 4- to 8-membered heterocyclic ring moiety to form a spiro structure; or
(d) R 1 and R 2 taken together with two or more adjacent ring atoms of the Y and Z-containing ring moiety can form an optionally substituted 4- to 9-membered heterocyclic monocyclic or bicyclic ring moiety fused to the Y and Z-containing ring moiety;
wherein each of said optionally substituted 4- to 9-membered heterocyclic ring moieties comprising R 1 and R 2 is optionally singly or doubly substituted with substituents independently selected from the group consisting of C 1 -C 6 alkyl, —C 1 -C 6 alkoxy, optionally substituted phenyl, oxo, —OH, —Cl, —F, —NH 2 , —NO 2 , —CN, —COOH, and amidino;
provided that when the Y and Z-containing ring moiety is a six or seven membered ring comprising a single ring heteroatom and when one of Y and Z is C and the other of Y and Z is N, and e is zero, then R 1 is not —OH, and R 1 and R 2 are not both —H;
provided further that when the Y and Z-containing ring moiety is a six membered ring comprising two ring heteroatoms, both Y and Z are N, W is null, and —V e (R 1 )(R 2 ) is attached to Z, then —V e (R 1 )(R 2 ) is selected from the group consisting of amidino, C 1 -C 6 alkyl-substituted amidino, dihydroimidazole, —CH 2 COOH, and —H 2 C(O)NH 2 ; and
lastly, provided that if the Y and Z-containing ring moiety is a six membered ring comprising two ring heteroatoms, wherein both Y and Z are N and W is null, or if the Y and Z-containing ring moiety is a six membered aromatic ring comprising a single ring heteroatom, which heteroatom is N, then, when e is zero, R 1 and R 2 are not both —H.
2. The method of claim 1 wherein W is null, Y is N and Z is C.
3. The method of claim 1 wherein the Y and Z-containing ring moiety is a six-membered saturated ring comprising a single ring heteroatom.
4. The method of claim 1 wherein Y and Z are both N and are the only ring heteroatoms in the Y and Z-containing ring moiety.
5. The method of claim 4 wherein e is zero and R 1 and R 2 taken together with zero, one or two ring atoms of the Y and Z-containing ring moiety comprise a monocyclic or bicyclic 4-9 membered heterocyclic ring moiety.
6. The method of claim 4 wherein R 1 and R 2 taken together with one ring atom of the Y and Z-containing ring moiety comprise a 4- to 8-membered heterocyclic ring moiety which with the Y and Z-containing ring moiety forms a spiro structure and W is null.
7. The method of claim 1 wherein e is zero and R 1 and R 2 are bonded directly to the same ring atom.
8. The method of claim 1 , wherein R 1 is H, OH, —NH 2 , —COOH, —CH 2 COOH, C 1 -C 3 alkyl, amidino, C 1 -C 3 alkyl-substituted amidino, dihydroimidazole, D-Pro, D-Pro amide, or CONH 2 and wherein R 2 is H, —COOH, or C 1 -C 3 alkyl.
9. The method of claim 1 , wherein the moiety:
is selected from the group consisting of:
10. The method of claim 1 , wherein the moiety:
is selected from the group consisting of:
11. The method of claim 1 , wherein the pruritis (also known as pruritus) is selected from the group consisting of uremic pruritis, pruritis associated with atopic dermatitis, ocular pruritis, otic pruritis, insect bite pruritis, opioid-induced pruritis and pruritis in cholestasis.
12. The method of claim 1 , wherein the pruritis (also known as pruritus) is uremic pruritis.
13. The method of claim 1 , wherein the pruritis (also known as pruritus) is associated with chronic kidney disease.
14. The method of claim 1 , wherein the pruritis (also known as pruritus) is associated with end stage renal disease.
15. The method of claim 1 , wherein the pruritis (also known as pruritus) is associated with kidney dialysis.
16. The method of claim 1 , wherein the human patient or the mammal is undergoing hemodialysis and the pruritis (also known as pruritus) is chronic kidney disease-associated pruritis.